{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:21:41Z","timestamp":1783347701010,"version":"3.54.6"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Stroke has been a topic of extensive research due to its debilitating consequences and high mortality. New findings offer a deeper understanding of specific factors that affect post-stroke recovery and identify therapies that may facilitate this process. One such factor is post-stroke neuroinflammation, a complex and time-dependent process in which acute immune responses can cause significant secondary inflammatory damage if the process is prolonged. Microglia are neuronal immune cells that are highly reactive to cytokines in the neuroenvironment and can, in turn, affect the inflammatory cascades that originate after stroke, making them ideal candidates for immunomodulation in the brain. Many FDA-approved immunotherapies have been found to target distinct inflammatory signaling molecules and responders, including IL-6 inhibitors, IL-13 inhibitors, IL-12\/IL-23 inhibitors, B-cell modulators, type I interferon inhibitors, CAR T-cell therapy, calcineurin inhibitors, complement inhibitors, and JAK-STAT pathway inhibitors. The FDA-approved immunotherapies discussed in this review demonstrate potential in modulating the immune response after stroke by targeting key inflammatory pathways involved in secondary brain injury. Future research should focus on defining optimal therapeutic windows, identifying suitable patient populations, determining the most appropriate timing of therapy, and targeting specific immune mechanisms to balance the attenuation of harmful inflammation with the preservation of reparative processes.<\/jats:p>","DOI":"10.3390\/ijms27041700","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:16:38Z","timestamp":1770722198000},"page":"1700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-6490","authenticated-orcid":false,"given":"Eduardo","family":"\u00c1lvarez-Rivera","sequence":"first","affiliation":[{"name":"Microbiology and Immunology Department, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Rodr\u00edguez-Vega","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Col\u00f3n-Santiago","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeliz","family":"Romero-Ponce","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Umpierre-Lebr\u00f3n","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Roig-Opio","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Rosa-Arocho","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santiago-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez-Torres","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson G.","family":"Santiago-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Llorens-Mercado","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Acevedo-Rico","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Berm\u00fadez-Fosse","sequence":"additional","affiliation":[{"name":"Department of Science and Technology, Interamerican University, San Juan, PR 00919-1293, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiara","family":"Hern\u00e1ndez-Santisteban","sequence":"additional","affiliation":[{"name":"Department of Science and Technology, Interamerican University, San Juan, PR 00919-1293, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rodr\u00edguez-Castellanos","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Puerto Rico, San Juan, PR 00925-253, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Garc\u00eda-Calder\u00edn","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Puerto Rico, San Juan, PR 00925-253, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabyana","family":"G\u00f3mez-Irrizary","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Puerto Rico, San Juan, PR 00925-253, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-9117","authenticated-orcid":false,"given":"Solianne","family":"Mart\u00ednez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Neuroscience Department, Universidad Central del Caribe, Bayam\u00f3n, PR 00960-6032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics, 2020 update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maida, C.D., Norrito, R.L., Daidone, M., Tuttolomondo, A., and Pinto, A. (2020). Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186454"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.4103\/NRR.NRR-D-24-01456","article-title":"Neuroinflammation Strokes the Brain: A Double-Edged Sword in Ischemic Stroke","volume":"21","author":"Lombardozzi","year":"2025","journal-title":"Neural Regen. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41590-023-01711-x","article-title":"Analysis of brain and blood single-cell transcriptomics in acute and subacute phases after experimental stroke","volume":"25","author":"Shahanoor","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13151","DOI":"10.1111\/bpa.13151","article-title":"Friends or foes: The mononuclear phagocyte system in ischemic stroke","volume":"33","author":"Ziqing","year":"2023","journal-title":"Brain Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroscience.2024.02.007","article-title":"Microglial Inflammatory Mechanisms in Stroke: The Jury Is Still Out","volume":"550","year":"2024","journal-title":"Neuroscience"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2147\/JIR.S461795","article-title":"Microglia in Ischemic Stroke: Pathogenesis Insights and Therapeutic Challenges","volume":"17","author":"Shui","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_8","first-page":"43","article-title":"Neuroinflammation and M2 microglia: The good, the bad, and the inflamed","volume":"62","author":"Cherry","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_9","first-page":"1822","article-title":"Microglial M1\/M2 polarization dynamics","volume":"35","author":"Hu","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xu, S., Lu, J., Shao, A., Zhang, J.H., and Zhang, J. (2020). Glial Cells: Role of the Immune Response in Ischemic Stroke. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00294"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wang, Y., Leak, R.K., and Cao, G. (2022). Microglia-mediated neuroinflammation and neuroplasticity after stroke. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.980722"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e157678","DOI":"10.1172\/JCI157678","article-title":"Neuroprotection against ischemic stroke requires a specific class of early responder T cells in mice","volume":"132","author":"Cai","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_14","unstructured":"FDA (2025, December 22). CAR T-Cell Therapy Overview. U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_15","unstructured":"Bristol Myers Squibb (2025, April 10). Bristol Myers Squibb\u2019s Abecma (Idecabtagene Vicleucel) Becomes First CAR T-Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma. Available online: https:\/\/investors.bms.com\/iframes\/press-releases\/press-release-details\/2024\/Bristol-Myers-Squibbs-Abecma-idecabtagene-vicleucel-Becomes-First-CAR-T-Cell-Therapy-Approved-in-the-European-Union-in-Earlier-Lines-for-Triple-Class-Exposed-Relapsed-and-Refractory-Multiple-Myeloma\/default.aspx?."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer."},{"key":"ref_17","unstructured":"ImmunityBio (2025, April 10). ImmunityBio Announces FDA Approval of ANKTIVA\u00ae, First-In-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Available online: https:\/\/immunitybio.com\/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer\/."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2024). Sarilumab (Kevzara) for polymyalgia rheumatica. Med. Lett. Drugs Ther., 66, 77\u201378.","DOI":"10.58347\/tml.2024.1702c"},{"key":"ref_19","unstructured":"Enspryng (2025, April 10). How ENSPRYNG Works. Available online: https:\/\/www.enspryng.com."},{"key":"ref_20","first-page":"123","article-title":"Lebrikizumab in inflammatory diseases","volume":"153","author":"Corren","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomized, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1189\/jlb.1109766","article-title":"Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells","volume":"87","author":"Jin","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_23","first-page":"456","article-title":"Ustekinumab for immune modulation","volume":"62","author":"Houssiau","year":"2023","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicenter, double-blind, phase 2, randomized, controlled study","volume":"392","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A Review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_26","unstructured":"Canadian Agency for Drugs and Technologies in Health (2023). Belimumab (Benlysta): CADTH Reimbursement Review, Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_27","unstructured":"Genentech (2025, December 22). Ocrevus (Ocrelizumab) Prescribing Information. Available online: https:\/\/www.gene.com\/download\/pdf\/ocrevus_zunovo_prescribing.pdf."},{"key":"ref_28","unstructured":"AstraZeneca (2025, December 22). Anifrolumab (Saphnelo) Prescribing Information. Available online: https:\/\/medicalinformation.astrazeneca-us.com\/home\/therapy-area\/therapy-area-immunology\/saphnelo.html."},{"key":"ref_29","unstructured":"Tysabri (2025, April 10). How TYSABRI Works. Available online: https:\/\/www.tysabri.com."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomized, multicenter, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.4103\/1673-5374.390966","article-title":"Cav3.2 channel regulates cerebral ischemia\/reperfusion injury: A promising target for intervention","volume":"19","author":"Dai","year":"2024","journal-title":"Neural Regen Res."},{"key":"ref_32","unstructured":"ChemoCentryx (2025, December 22). Tavneos (Avacopan) Prescribing Information. Available online: https:\/\/www.chemo.com\/avacopan."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(22)00778-4","article-title":"Upadacitinib for ulcerative colitis","volume":"399","author":"Ananthakrishnan","year":"2022","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomized, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomized, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101489","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.hest.2023.02.003","article-title":"Immunotherapy as a treatment for stroke: Utilizing regulatory T cells","volume":"4","author":"Li","year":"2023","journal-title":"Brain Hemorrhages"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/brain\/awab439","article-title":"Precision medicine in stroke: Towards personalized outcome predictions using artificial intelligence","volume":"145","author":"Bonkhoff","year":"2021","journal-title":"Brain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jocn.2024.01.009","article-title":"The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: A systematic review","volume":"120","author":"Kazmi","year":"2024","journal-title":"J. Clin. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8-week induction therapy (U-ACHIEVE Maintenance): Overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_42","unstructured":"U.S. Food and Drug Administration (2025, April 10). ABECMA (Idecabtagene Vicleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"ref_43","unstructured":"U.S. Food and Drug Administration (2025, April 10). FDA D.I.S.C.O. Burst Edition: FDA Approval of Tecartus (Brexucabtagene Autoleucel) for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-tecartus-brexucabtagene-autoleucel-adult-patients-relapsed-or."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:21:31Z","timestamp":1770722491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041700"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041700","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}